Abstract Abstract Valsartan (Diovan®) is an oral angiotensin II-receptor antagonist with
specificity for the angiotensin II type 1 receptor subtype. It demonstrates antihypertensive …

The physiological role of the renin angiotensin aldosterone system (RAAS) is to maintain the
integrity of the cardiovascular system. The effect of angiotensin II is mediated via the …

Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce
mortality and cardiovascular morbidity among patients with myocardial infarction …

Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or
resulting in left ventricular dysfunction are at heightened risk for subsequent death and …

Background Actions of angiotensin II may contribute to the progression of heart failure
despite treatment with currently recommended drugs. We therefore evaluated the long-term …

Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for
patients who after myocardial infarction (MI) present with either heart failure (HF) or left …

OBJECTIVE: To evaluate the evidence for valsartan in the treatment of heart failure and
determine its need for formulary inclusion. DATA SOURCES: OVID and PubMed databases …

Heart failure (HF) still has a discouraging prognosis. Therapeutic strategies aim to reduce
mortality as well as slow the progression of the disease, improve symptoms and reduce the …

Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding
of angiotensin II to the angiotensin II type 1 receptor. The efficacy, tolerability and safety of …

Valsartan is an angiotensin receptor antagonist that specifically blocks the angiotensin II
type 1 receptors. It is an effective and well-tolerated once-daily antihypertensive agent, with …